Clinical trial
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects…
NCT00479765 · Boston Scientific Corporation, Industry · Terminated
Key facts
| NCT number | NCT00479765 |
|---|---|
| Title | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma |
| Official title | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma |
| Lead sponsor | Boston Scientific Corporation, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Brain Neoplasms |
| Intervention type | Drug |
| Interventions | OncoGel (ReGel/Paclitaxel) |
| Enrollment | 4 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | May 28, 2007 |
| Last update posted | Jun 22, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: